NO994998L - Fusjonsproteiner - Google Patents

Fusjonsproteiner

Info

Publication number
NO994998L
NO994998L NO994998A NO994998A NO994998L NO 994998 L NO994998 L NO 994998L NO 994998 A NO994998 A NO 994998A NO 994998 A NO994998 A NO 994998A NO 994998 L NO994998 L NO 994998L
Authority
NO
Norway
Prior art keywords
fusion proteins
tgf
treat
variety
methods
Prior art date
Application number
NO994998A
Other languages
English (en)
Norwegian (no)
Other versions
NO994998D0 (no
Inventor
Philip Gotwals
Victor Koteliansky
Richard Cate
Michelle Sanicola-Nadel
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO994998D0 publication Critical patent/NO994998D0/no
Publication of NO994998L publication Critical patent/NO994998L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
NO994998A 1997-04-18 1999-10-14 Fusjonsproteiner NO994998L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4464197P 1997-04-18 1997-04-18
PCT/US1998/007587 WO1998048024A1 (en) 1997-04-18 1998-04-16 Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins

Publications (2)

Publication Number Publication Date
NO994998D0 NO994998D0 (no) 1999-10-14
NO994998L true NO994998L (no) 1999-12-20

Family

ID=21933495

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994998A NO994998L (no) 1997-04-18 1999-10-14 Fusjonsproteiner

Country Status (22)

Country Link
US (1) US20050203022A1 (et)
EP (1) EP0975771B1 (et)
JP (2) JP2001515360A (et)
KR (1) KR20010006534A (et)
CN (1) CN1257545A (et)
AT (1) ATE366816T1 (et)
AU (1) AU737106B2 (et)
BR (1) BR9808934A (et)
CA (1) CA2286933A1 (et)
DE (1) DE69838061T2 (et)
DK (1) DK0975771T3 (et)
EA (1) EA199900947A1 (et)
EE (1) EE9900492A (et)
ES (1) ES2289778T3 (et)
IL (1) IL132249A0 (et)
IS (1) IS5217A (et)
NO (1) NO994998L (et)
NZ (1) NZ500284A (et)
PL (1) PL336306A1 (et)
PT (1) PT975771E (et)
TR (1) TR199902878T2 (et)
WO (1) WO1998048024A1 (et)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6492325B1 (en) 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
AU4572899A (en) * 1998-06-16 2000-01-05 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
AU7322600A (en) 1999-09-17 2001-04-24 Tgt Laboratories, S.A. De C.V. Recombinant adenoviral vectors and their utilization in the treatment of varioustypes of hepatic, renal and pulmonary fibrosis and hypertrophic scars
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
MXPA00011713A (es) 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
ATE542545T1 (de) * 2001-05-24 2012-02-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
EP2862867A3 (en) 2005-10-25 2015-08-05 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
EP2230252A1 (en) 2006-03-13 2010-09-22 The Johns Hopkins University Augmentation of endothelial thromboresistance
US20100098668A1 (en) * 2006-09-29 2010-04-22 Northshore University Health System Oncolytic Adenoviruses and Uses Thereof
ES2538265T3 (es) 2006-10-03 2015-06-18 Genzyme Corporation Anticuerpos contra TGF-beta para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
WO2008157367A1 (en) * 2007-06-15 2008-12-24 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
WO2011100460A2 (en) * 2010-02-11 2011-08-18 Ecole Polytechnique Federale De Lausanne Ccr7 ligand delivery and co-delivery in immunotherapy
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN103429732B (zh) 2010-12-27 2015-09-16 Lsip基金运营联合公司 iPS细胞及其制造方法
CN102175501A (zh) * 2011-01-07 2011-09-07 山东省农业科学院作物研究所 用于显微镜观察的植物样品的前处理方法
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
CN102898508B (zh) * 2011-08-12 2014-04-30 北京大学第一医院 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
CA2853484C (en) 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
NZ722352A (en) 2012-02-15 2022-05-27 Ecole Polytechnique Fed Lausanne Epfl Erythrocyte-binding therapeutics
US20150056199A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
EP3064222B1 (en) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
EP3071215B1 (en) 2013-11-21 2020-01-08 The Brigham and Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
AR098827A1 (es) 2013-12-19 2016-06-15 Consejo Nac De Investig Científicas Y Técnicas (Conicet) ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
HUE054873T2 (hu) * 2014-02-10 2021-10-28 Merck Patent Gmbh Célzott TGF-béta-gátlás
ES2874884T3 (es) 2014-02-21 2021-11-05 Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto Compuestos terapéuticos dirigidos a la glucosa
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3693004A1 (en) 2014-08-01 2020-08-12 The Brigham and Women's Hospital, Inc. An inhibitor of gdf-15 for use in treating fibrosis
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
KR20180035884A (ko) * 2015-08-04 2018-04-06 악셀레론 파마 인코포레이티드 골수증식성 장애를 치료하기 위한 방법
CA2996996A1 (en) * 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
CN118307682A (zh) * 2016-09-27 2024-07-09 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
CA3055156A1 (en) * 2017-03-02 2018-09-07 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
WO2018204594A1 (en) 2017-05-04 2018-11-08 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EA202090838A1 (ru) 2017-09-27 2020-08-28 Эписентарикс, Инк. Иммуномодулирующие слитые белки
CN112119157A (zh) 2018-03-06 2020-12-22 宾夕法尼亚大学董事会 前列腺特异性膜抗原car及其使用方法
CA3093468A1 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
CN111867612A (zh) * 2018-03-26 2020-10-30 阿尔托生物科学有限责任公司 抗PDL1、IL-15和TGF-β受体组合分子
KR20210042909A (ko) 2018-07-09 2021-04-20 프레시전 인코포레이티드 융합 구조물 및 그의 이용 방법
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20220362333A1 (en) * 2019-07-26 2022-11-17 Board Of Trustees Of Michigan State University Methods Of Preventing Or Treating Fatty Degeneration Of Skeletal Muscle
EP4021928A4 (en) * 2019-08-29 2023-09-20 NantBio, Inc. MODIFIED N-810 AND ASSOCIATED METHODS
MX2022005491A (es) * 2019-11-05 2022-07-27 Acceleron Pharma Inc Tratamientos contra esclerosis sistémica.
US20230365653A1 (en) * 2020-07-24 2023-11-16 Mabwell (shanghai) Bioscience Co., Ltd. Tgf-beta rii mutant and fusion protein thereof
AU2023210700A1 (en) 2022-01-28 2024-08-15 35Pharma Inc. Activin receptor type iib variants and uses thereof
WO2023206188A1 (en) * 2022-04-28 2023-11-02 Wenzhou Prarucom Bio-Chemical Technology Co. Method for alleviating pulmonary fibrosis using epidermal growth factor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4874702A (en) * 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
JPH08504763A (ja) * 1992-10-29 1996-05-21 セルトリックス ファーマシューティカルズ，インコーポレイテッド 治療薬としてのＴＧＦ−βレセプターフラグメントの使用
AU687790B2 (en) * 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

Also Published As

Publication number Publication date
WO1998048024A1 (en) 1998-10-29
US20050203022A1 (en) 2005-09-15
JP2001515360A (ja) 2001-09-18
DE69838061D1 (de) 2007-08-23
TR199902878T2 (xx) 2000-02-21
NZ500284A (en) 2001-09-28
DE69838061T2 (de) 2008-03-13
BR9808934A (pt) 2000-08-01
PL336306A1 (en) 2000-06-19
AU7120898A (en) 1998-11-13
IL132249A0 (en) 2001-03-19
CA2286933A1 (en) 1998-10-29
CN1257545A (zh) 2000-06-21
KR20010006534A (ko) 2001-01-26
IS5217A (is) 1999-10-15
ES2289778T3 (es) 2008-02-01
EE9900492A (et) 2000-06-15
NO994998D0 (no) 1999-10-14
JP2008106076A (ja) 2008-05-08
EA199900947A1 (ru) 2000-04-24
ATE366816T1 (de) 2007-08-15
AU737106B2 (en) 2001-08-09
DK0975771T3 (da) 2007-10-22
EP0975771B1 (en) 2007-07-11
EP0975771A1 (en) 2000-02-02
PT975771E (pt) 2007-10-01

Similar Documents

Publication Publication Date Title
NO994998D0 (no) Fusjonsproteiner
KR950700779A (ko) 단백질의 정제방법(Protein purification)
CY2007012I2 (el) Αντισωματα anti-vegf
DE69536078D1 (de) Inhibitoren
DK0911416T3 (da) Fremgangsmåde til fremstilling af protein
FI20070170A (fi) Immunoglobuliinit, joista puuttuvat kevyet ketjut
DK1200479T3 (da) Multiple cytokin-antistof-komplekser
DE69833014D1 (de) Menschliche toll homologen
PT1027339E (pt) Metodo e reagentes para a n-alquilacao de ureidos
DK0917879T3 (da) Forbedret fremgangsmåde til stabilisering af proteiner
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
NO960611D0 (no) Bitumenholdig blanding
ATE285474T1 (de) Haemophilus adhäsionsproteinen
CY1106887T1 (el) Πρωτεϊνες συντηξης τυπου ii tgf-b υποδοχεα/σταθερης περιοχης ανοσοσφαιρινης
ATE325873T1 (de) Androgenrezeptor-komplex assoziiertes protein
BR9805546B1 (pt) regulador de alternador polifásico de veìculo automotor.
KR970001929U (ko) 도로안내용 반사판
KR970016491U (ko) 스프링 타입용 지그
ES1036274Y (es) Conjunto de piezas de suspension de lamparas.
BR1100492A (pt) variantes de imunoglobulina.
BR1100555B1 (pt) anticorpos monoclonais humanizados.
KR970032618U (ko) 자동차의 전조등 조정장치
BR1100504A (pt) anticorpos anti-ige.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application